Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence.
Détails
ID Serval
serval:BIB_A33BC32F3E03
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence.
Périodique
Archives of Physical Medicine and Rehabilitation
ISSN
0003-9993 (Print)
ISSN-L
0003-9993
Statut éditorial
Publié
Date de publication
2007
Volume
88
Numéro
5
Pages
646-652
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
OBJECTIVE: To assess the reliability, validity, responsiveness, and minimally important difference (MID) of the Incontinence Quality of Life (I-QOL) questionnaire in patients with urinary incontinence due to neurogenic detrusor overactivity.
DESIGN: Randomized, double-blind, multicenter, placebo-controlled study.
SETTING: Eight centers across Belgium, France, and Switzerland.
PARTICIPANTS: Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed on oral anticholinergics. Fifty-nine patients (spinal cord injury, n=53; multiple sclerosis, n=6) were enrolled.
INTERVENTION: Single dose of botulinum toxin type A (Botox) (200 or 300 U) or placebo.
MAIN OUTCOME MEASURES: I-QOL questionnaire completed at screening and over a 24-week post-treatment period.
RESULTS: The Cronbach alpha ranged from .79 to .93, indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinence patients. No item had more than 5.1% missing or out of range values. With the exception of 2 items, questions showed acceptable item-scale correlation and scaling success results varied by domain. Post-treatment correlations indicated acceptable construct validity. The I-QOL was responsive to improvements in symptoms. MID values ranged from 4 to 11 points.
CONCLUSIONS: Results suggest that I-QOL is a reliable, valid, and responsive measure of incontinence-related QOL in neurogenic patients.
DESIGN: Randomized, double-blind, multicenter, placebo-controlled study.
SETTING: Eight centers across Belgium, France, and Switzerland.
PARTICIPANTS: Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed on oral anticholinergics. Fifty-nine patients (spinal cord injury, n=53; multiple sclerosis, n=6) were enrolled.
INTERVENTION: Single dose of botulinum toxin type A (Botox) (200 or 300 U) or placebo.
MAIN OUTCOME MEASURES: I-QOL questionnaire completed at screening and over a 24-week post-treatment period.
RESULTS: The Cronbach alpha ranged from .79 to .93, indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinence patients. No item had more than 5.1% missing or out of range values. With the exception of 2 items, questions showed acceptable item-scale correlation and scaling success results varied by domain. Post-treatment correlations indicated acceptable construct validity. The I-QOL was responsive to improvements in symptoms. MID values ranged from 4 to 11 points.
CONCLUSIONS: Results suggest that I-QOL is a reliable, valid, and responsive measure of incontinence-related QOL in neurogenic patients.
Mots-clé
Adult, Aged, Botulinum Toxins, Type A/therapeutic use, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Multiple Sclerosis/complications, Psychometrics/methods, Quality of Life, Questionnaires, Reproducibility of Results, Spinal Cord Injuries/complications, Urinary Bladder, Neurogenic/drug therapy, Urinary Bladder, Neurogenic/etiology
Pubmed
Web of science
Création de la notice
05/11/2014 13:13
Dernière modification de la notice
20/08/2019 16:08
Données d'usage
